Olgotrelvir, a dual inhibitor of SARS-CoV-2 M pro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.

MLA

Mao, Long, et al. “Olgotrelvir, a Dual Inhibitor of SARS-CoV-2 M pro and Cathepsin L, as a Standalone Antiviral Oral Intervention Candidate for COVID-19.” Med (New York, N.Y.), vol. 5, no. 1, Jan. 2024, p. 42. EBSCOhost, https://doi.org/10.1016/j.medj.2023.12.004.

APA

Mao, L., Shaabani, N., Zhang, X., Jin, C., Xu, W., Argent, C., Kushnareva, Y., Powers, C., Stegman, K., Liu, J., Xie, H., Xu, C., Bao, Y., Xu, L., Zhang, Y., Yang, H., Qian, S., Hu, Y., Shao, J., … Xu, X. (2024). Olgotrelvir, a dual inhibitor of SARS-CoV-2 M pro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19. Med (New York, N.Y.), 5(1), 42. https://doi.org/10.1016/j.medj.2023.12.004

Chicago

Mao, Long, Namir Shaabani, Xiaoying Zhang, Can Jin, Wanhong Xu, Christopher Argent, Yulia Kushnareva, et al. 2024. “Olgotrelvir, a Dual Inhibitor of SARS-CoV-2 M pro and Cathepsin L, as a Standalone Antiviral Oral Intervention Candidate for COVID-19.” Med (New York, N.Y.) 5 (1): 42. doi:10.1016/j.medj.2023.12.004.